*Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002 Dec;38 (18) :2362-70. , URL: https://www.ncbi.nlm.nih.gov/pubmed/12460779?dopt=, *Gulubova M: Immunohistochemical localization of collagen type III and type IV, laminin, tenascin and alpha-smooth muscle actin (alphaSMA) in the human liver in peliosis. Pathol Res Pract. 2002;198 (12) :803-12., URL: https://www.ncbi.nlm.nih.gov/pubmed/12608657?dopt=, *Faustino AM, van Garderen E, Schalken JA, Nederbragt H: Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. J Comp Pathol. 2002 Jan;126 (1) :1-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/11814316?dopt=, *Tokes AM, Hortovanyi E, Csordas G, Kulka J, Mozes G, Hatalyak A, Kadar A: Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res. 1999 Jan-Feb;19 (1A) :175-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/10226540?dopt=, *Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Scott Budinger GS, Raparia K, Tamaki Z, Varga J: Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016 Jun 3;7:11703, URL: https://pubmed.ncbi.nlm.nih.gov/27256716/, *Seyger MM, van Bruggen MC, Hardeman HK, van den Hoogen FH, Berden JH, van den Born J, de Jong EM: Decreased staining of heparan sulfate in non-lesional skin of a subgroup of patients with systemic lupus erythematosus. Acta Derm Venereol. 1998 Sep;78 (5) :326-30., URL: https://pubmed.ncbi.nlm.nih.gov/9779246/, *Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK: Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997 Aug;137 (2) :171-8 , URL: https://pubmed.ncbi.nlm.nih.gov/9292062/, *Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, de Jongh GJ, Schalkwijk J: Tenascin expression in basal cell carcinoma. Br J Dermatol. 1992 Dec;127 (6) :571-4, URL: https://pubmed.ncbi.nlm.nih.gov/1282358/, *Mansour RG, Stamper L, Jaeger F, McGuire E, Fouda G, Amos J, Barbas K, Ohashi T, Alam SM, Erickson H, Permar SR: The presence and anti-HIV-1 function of tenascin C in breast milk and genital fluids. PLoS One. 2016 May 16;11 (5) :e0155261. , URL: https://pubmed.ncbi.nlm.nih.gov/27182834/, *Latijnhouwers MA, Bergers M, Kuijpers AL, van der Vleuten CJ, Dijkman H, van de Kerkhof PC, J Schalkwijk: Tenascin-C is not a useful marker for disease activity in psoriasis. Acta Derm Venereol. 1998 Sep;78 (5) :331-4., URL: https://pubmed.ncbi.nlm.nih.gov/9779247/, *Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, Bristow J: A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med. 2001 Oct 18;345 (16) :1167-75., URL: https://pubmed.ncbi.nlm.nih.gov/11642233/
